Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsMEX:BNGO 56 Cyclically Adjusted PS Ratio is 0.00 as of Aug. 06, 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 56/100 and a GF Value™ of MXN26.58 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 522 Medical Devices & Instruments companies, Bionano Genomics ranks worse than 191570.69% on this metric.
The historical rank and industry rank for Bionano Genomics's Cyclically Adjusted PS Ratio or its related term are showing as below:
MEX:BNGO's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.26 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Bionano Genomics's adjusted revenue per share data of for the fiscal year that ended in Dec25 was MXN94.271. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN9,987.68 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Bionano Genomics (MEX:BNGO) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Bionano Genomics Cyclically Adjusted PS Ratio Related Terms
Bionano Genomics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics Cyclically Adjusted PS Ratio Chart
MEX:BNGO vs RGNT, UEEC, FEMY: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Cyclically Adjusted PS Ratio falls into.
Bionano Genomics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Bionano Genomics's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.00 mean?
Bionano Genomics (MEX:BNGO) has a Cyclically Adjusted PS Ratio of 0.00 as of Aug. 06, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bionano Genomics and its competitors. According to the industry distribution chart, Bionano Genomics ranks #999999 out of 522 companies in the Medical Devices & Instruments industry.
Is Bionano Genomics' Cyclically Adjusted PS Ratio too high?
Bionano Genomics' current Cyclically Adjusted PS Ratio is 0.00. Based on the distribution chart, Bionano Genomics ranks #999999 out of 522 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionano Genomics has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Cyclically Adjusted PS Ratio compare to RGNT and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #999999 out of 522 companies for Cyclically Adjusted PS Ratio. This places Bionano Genomics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.26, based on 522 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Cyclically Adjusted PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN26.58, compared to a current price of MXN19.09 — trading 28.2% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.00. Bionano Genomics' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Cyclically Adjusted PS Ratio is 0.00 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued.
The current stock price of MXN19.09 is trading 28.2% below its estimated GF Value™ of MXN26.58.
GuruFocus considers Bionano Genomics to be Modestly Undervalued.
Key valuation signals for MEX:BNGO:
Cyclically Adjusted PS Ratio: 0.00
GF Value™: MXN26.58 vs. price of MXN19.09 (28.2% below fair value)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
56GF Score
Get the complete analysis for MEX:BNGO
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
